Belvedere ML43000 (Neovascular Age-Related Macular Degeneration) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to monitor the health of the cornea in participants with neovascular age-related macular degeneration (nAMD), also know as wet AMD, who receive an eye implant that continuously delivers the drug ranibizumab into the back of the eye.
Neovascular Age-Related Macular Degeneration (nAMD) AKA "Wet AMD"
Who Can Participate in the Study?
Adults ages 50+ who:
- Are diagnosed with nAMD (within 18 months of joining study)
- Have not received treatment with intravitreal corticosteroids
- Have not had an intraocular surgery (including cataract surgery) within 6 months of joining the study
For more information about who can be in this study, please contact the study team at DEC-RA@duke.edu.
What is Involved?
If you choose to join the study, you will:
- Get an eye implant, filled with ranibizumab
- Be enrolled in the study for about 1 year
- Visit our clinic at the Duke Eye Center up to 13 times during the study
At various visits, you will have blood tests, eye exams, and vision tests.